SoftBank founder Masayoshi Son speaks in futuristic terms about his company, but the success of his late-stage VC fund is still unknown.Technologyread more
Reports of Tesla vehicles spontaneously catching fire could make customers wary of EVs just as the industry ramps up production plans.Autosread more
Amazon's large and flashy investments stand out from those of its tech peers over the past year.Technologyread more
Huawei Technologies will immediately lose access to updates to the Android operating system, a source close the matter told Reuters.Technologyread more
Consumer IPOs from Snap to Uber have been disappointing and serve as a reminder that private investors are making all the money.Technologyread more
The 2019 PGA Championship wraps up on Sunday, May 19. Here's how much money the champion will earn.Earnread more
China's currency has been an important barometer for progress in U.S.-Chinese trade talks, and right now it's signaling things aren't going well.Market Insiderread more
The move comes after star runner Alysia Montaño's May 12 op-ed in the New York Times in which she detailed her experiences with Nike.Retailread more
While the prolonged fight has been devastating to an already-struggling agriculture industry, there's little indication Trump is paying a political price.Traderead more
The outrage has even inspired a Change.org petition called "Remake Game of Thrones Season 8 with competent writers," with over half-a-million signatories and climbing.Entertainmentread more
The company's comments Friday come after the White House said U.S.Trade Representative Robert Lighthizer will "address the threatened impairment" of national security from...Autosread more
Craig Thompson, chief executive of Memorial Sloan Kettering Cancer Center, resigned from the board of drugmaker Merck on Tuesday, after questions about the cancer center's ties to the pharmaceutical industry.
The New York Times previously reported Thompson's resignation from Merck and from lab services company Charles River Laboratories International.
The move follows the resignation of Sloan Kettering's chief medical officer, Jose Baselga, in September, after a New York Times and Pro Publica investigation revealed that he had not disclosed millions of dollars in payments from health-care companies in many of his research articles.
Baselga also resigned from the board of Bristol-Myers Squibb.
Merck said in a statement that Thompson's contributions on its board "demonstrate why it is so important to have leaders from the medical community represented."
The drug company said the size of its board will shrink to 12 directors after Thompson's resignation.
Memorial Sloan Kettering did not immediately comment on Thompson's stepping down from the boards. Charles River Laboratories could not be immediately reached for comment.